Shelby Derene Reed
Professor in Population Health Sciences

Shelby Reed, PhD, RPh is Professor in Population Health Sciences and Medicine at Duke University and Director of the Preference Evaluation Research (PrefER) Group at the Duke Clinical Research Institute.  She also is core faculty and serves on the executive committee at the Duke-Margolis Center for Health Policy. Dr. Reed has 20 years of experience leading multidisciplinary health outcomes research studies. Dr. Reed has extensive expertise in designing and conducting trial-based and model-based cost-effectiveness analyses of diagnostics, drugs and patient-centered interventions. In evaluating health policy issues, she has developed computer models to evaluate the economic impact of trends in clinical trial design, changes in reimbursement policies, a new financing scheme to spur drug development for ultra-rare conditions, and the societal value of alternative approaches to identifying drug safety problems. Over the last several years, her research has increasingly focused on stated-preference studies to evaluate benefit-risk tradeoffs, patient-centered value, and their application in comparative effectiveness research and clinical decision making.  Dr. Reed earned pharmacy and doctoral degrees from the University of Maryland and completed her training in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. She serves on editorial advisory boards for Value in Health and Health Services Research.  She served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in 2017-2018.

Shelby Reed, PhD, RPh is Professor in Population Health Sciences and Medicine at Duke University and Director of the Preference Evaluation Research (PrefER) Group at the Duke Clinical Research Institute.  She also is core faculty and serves on the executive committee at the Duke-Margolis Center for Health Policy. Dr. Reed has 20 years of experience leading multidisciplinary health outcomes research studies. Dr. Reed has extensive expertise in designing and conducting trial-based and model-based cost-effectiveness analyses of diagnostics, drugs and patient-centered interventions. In evaluating health policy issues, she has developed computer models to evaluate the economic impact of trends in clinical trial design, changes in reimbursement policies, a new financing scheme to spur drug development for ultra-rare conditions, and the societal value of alternative approaches to identifying drug safety problems. Over the last several years, her research has increasingly focused on stated-preference studies to evaluate benefit-risk tradeoffs, patient-centered value, and their application in comparative effectiveness research and clinical decision making.  Dr. Reed earned pharmacy and doctoral degrees from the University of Maryland and completed her training in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. She serves on editorial advisory boards for Value in Health and Health Services Research.  She served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in 2017-2018. she is currently Chair of ISPOR's Health Science Policy Council.

 

Areas of expertise: Health Economics, Health Measurement, Stated Preference Research, Health Policy, and Health Services Research

Current Appointments & Affiliations

Contact Information

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.